###### Strengths and limitations of this study

-   The study is the first national, prospective, observational study in China, aiming to describe the use of revascularisation procedures, and the association of treatment and its appropriateness with patients' 1-year outcomes.

-   The study seeks to evaluate a broad range of outcomes, including major adverse cardiac and cerebrovascular events at 1 year, and patient-reported outcome measures, assessed with the Chinese-language Seattle Angina Questionnaire (SAQ) and EuroQoL questionnaire (EQ-5D).

-   Rigorous data quality auditing methods are used to evaluate the quality of data.

-   The participating sites are all large teaching hospitals, which may only represent large cardiac care centres in China and may not be reflective of the care patients receive in smaller or rural hospitals.

Introduction {#s1}
============

With an ageing population and an increasing prevalence of cardiovascular risk factors,[@R1] [@R2] China is experiencing a rapid rise in coronary artery disease (CAD).[@R1] [@R3] Furthermore, the prevalence of the most complex and morbid diseases, three-vessel disease (3VD) and left main (LM) disease, together referred to as 'complex coronary artery disease (CCAD)', is growing concomitantly.[@R6] The major treatment strategies for CCAD, coronary revascularisation via coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI), has substantially increased in China. In 2013, nearly 30 000 CABG and 390 000 PCI procedures were performed,[@R10] [@R11] and the volumes of CABG and PCI continue to increase annually at the rates of about 8% and 15%, respectively.[@R10] Though the introduction of drug-eluting stents has decreased restenosis rates of PCI,[@R13] recent randomised controlled trials have failed to show significant advantages of PCI over CABG for CCAD specifically.[@R8] [@R14] Multiple recent guidelines designate CABG in combination with optimal medical therapy (OMT) as the standard of care for CCAD.[@R7] [@R15]

Studies of real-world practice in Western countries have identified patterns of inappropriate revascularisation use among patients with CCAD, especially use of PCI.[@R18] In China, the PCI/CABG ratio is 13:1, much higher than the PCI/CABG ratio of 3:1 in many other countries.[@R23] This high ratio may partly be due to the limited number of cardiac surgery facilities and surgeons, as compared with the number of hospitals and cardiologists with the capability to perform PCI. There are approximately 700 hospitals with the ability to perform cardiac surgery, and over 1000 hospitals with PCI capability in China.[@R11] [@R24] Also, patients themselves may be choosing PCI over CABG given the upfront expense necessary in China\'s healthcare system, which demands as much as \$15 000 prior to CABG, as well as perceptions about the anticipated pain and suffering resulting from an open-heart procedure.[@R25] However, given the inadequate quality measurements and incentives to follow clinical guidelines for procedures in China,[@R26] as well a disproportionate increase of PCI versus CABG among the majority of regions and hospitals,[@R10] [@R27] [@R28] the high ratio of PCI to CABG has raised critical concerns about the selection of the type of revascularisation procedures for CCAD.

The Chinese version of PCI guidelines was published in 2012.[@R29] Foreign guidelines are also widely accepted in China.[@R15] [@R16] However, gaps in knowledge remain with regard to adherence of physicians to current guidelines and appropriate use criteria of the chosen treatment. Thoroughly evaluating this information, as well as understanding the variation among regions and hospitals in China, is critical to developing evidence-based and effective quality improvement initiatives for the decision-making process and quality of care for CCAD in Chinese populations.[@R30] Additionally, little is known about variations in treatment decisions, the key predictors of outcomes in order to benchmark levels of achievable outcomes. One study, based on China Cardiovascular Surgery Registry data, identified generally low mortality and complication rates after CABG, but these rates varied substantially by hospital and region.[@R28] Moreover, one single-centre retrospective observational study demonstrated lower rates of adverse events for CABG as compared with PCI using drug-eluting stents for multivessel disease.[@R31] However, there are no prospective studies evaluating the selection of the type of treatment (CABG, PCI and/or optimal medical therapy) for patients with CCAD in cardiac centres with the capacity to perform both CABG and PCI. We know little about outcomes after these two treatments, including patient-reported outcome measures (PROMs).

To address these gaps, we have leveraged the China Patient-centered Evaluative Assessment of Cardiac Events (China PEACE) research network to perform the China PEACE-Prospective Study of 3-Vessel Disease (China PEACE-3VD). As previously described,[@R32] [@R33] China PEACE is a collaborative effort among the China National Center for Cardiovascular Diseases (NCCD), the Yale-New Haven Hospital Center for Outcomes Research and Evaluation, the Chinese government and a national network of Chinese hospitals. The goal of this network is to generate new knowledge relevant to practice and policy, and to translate this knowledge into action, to improve care and outcomes for patients with cardiovascular disease.

China PEACE-3VD has a plan to consecutively register over 4000 patients with a diagnosis of 3VD and/or left-main disease by elective coronary angiography at 24 large cardiovascular centres with capability to perform both CABG and PCI in China, to collect data from medical records and SYNTAX Scores, and invite patients to the prospective cohort to conduct 1-year follow-up on major events, including cardiac events and PROMs. China PEACE-3VD is the first national, prospective, observational study of CCAD patients in China, aiming to describe the use of revascularisation procedures, the association of treatment and its appropriateness with patients' 1-year outcomes, and the variation of treatments and outcomes among regions and sites.

There are three major goals of the China PEACE-3VD study. First, we aim to describe the treatment choice for each patient with CCAD in large cardiac care centres in China. Second, we aim to assess the alignment of treatment with the guidelines and appropriate use criteria (see online supplementary materials), and to evaluate the variation of treatment appropriateness among hospitals.[@R7] [@R15] [@R17] [@R34] Third, we aim to evaluate the relationship between appropriateness of treatment choices and patient outcomes including PROMs over 1 year. Additionally, we want to provide insights into key predictors of treatment strategy choices in-hospital and 1-year outcome for CCAD by evaluating the associations of demographic, clinical risk factors, coronary anatomy complexity (SYNTAX Score),[@R39] and psychosocial and socioeconomic factors, with patient outcomes. Further, we hope that the cohort of China PEACE-3VD can be used to assess the applicability of previously developed risk evaluation models (including the logistic EuroSCORE, SinoSCORE and SYNTAX Scores) for both PCI and CABG in the Chinese population. We will partner with the Chinese government, Chinese Medical Associations and other national and international organisations to disseminate findings from the China PEACE-3VD study to improve the care and outcomes for patients with CCAD.[@R39] We hope that this study will benchmark levels of achievable outcomes to leverage quality improvement initiatives throughout the country.

Methods and analysis {#s2}
====================

Design overview {#s2a}
---------------

China PEACE-3VD consecutively enrolled patients with the diagnosis of CCAD by elective (scheduled 24 h prior) coronary artery angiography without previous history of CABG or PCI from a broad network of hospitals over a 1-year enrolment period (December 2012 to December 2013) into the prospective cohort. Trained coordinators at each site interviewed patients during their index hospitalisation, as well as at 1-month, 6-month and 12-month intervals following hospital discharge ([figure 1](#BMJOPEN2015009743F1){ref-type="fig"}). The core lab based at Fuwai Hospital reviewed and calculated all SYNTAX Scores for each patient\'s index coronary angiography. Medical records were scanned at each participating site and then transferred to the coordinating centre. The 'Real Data Medical Research Inc' group,[@R43] under the supervision of the coordinating centre, is centrally abstracting data from each medical record.

![Design and study overview of China PEACE-3VD. CABG, coronary artery bypass grafting; Meds indicates medical therapy; CCAD, complex coronary artery disease; EQ-5D, EuroQol Questionnaire; PCI, percutaneous coronary intervention; PEACE-3VD, Patient-centered Evaluative Assessment of Cardiac Events three-vessel disease study; SAQ, Seattle Angina Questionnaire.](bmjopen2015009743f01){#BMJOPEN2015009743F1}

Additionally, patients who were not enrolled in the prospective cohort were added to a registry cohort, with only their medical record data and SYNTAX Scores collected.

Study population and recruitment {#s2b}
--------------------------------

From December 2012 to December 2013, the cardiac catheterisation physicians at each local hospital routinely reviewed all elective coronary angiograms (scheduled 24 h before the procedure) within 2 days of the procedure, to identify patients diagnosed with coronary artery disease with significant stenosis (≥50% diameter) in three major coronary arteries or significant stenosis (≥50% diameter) in the left main coronary artery, based on the interventional cardiologist\'s interpretation. Exclusion criteria were as follows: history of prior revascularisation, an acute myocardial infarction within 24 h prior to the current procedure, or those who had been previously enrolled in the China PEACE-3VD study. Once patients were identified as eligible, we assigned them a unique study ID. Since an important component of the study was to perform a detailed, in-person, patient interview, patients needed to be prospectively identified as early as possible during their hospitalisation.

We invited all eligible patients to enrol during their hospitalisation. We did not invite patients who were critically ill in the intensive care unit, nor those patients unable to understand the study questions due to cognitive function or language barriers, nor those who had already been discharged. We enrolled consenting patients into the prospective cohort, and then registered all remaining patients into the registry cohort. This registry cohort will be used to assess the representativeness of the study and will also be used to assess the entire range of treatment choices.

Site network {#s2c}
------------

A research network was established in collaboration with 24 tertiary hospitals located in 17 provinces throughout China ([figure 2](#BMJOPEN2015009743F2){ref-type="fig"} and online supplementary materials). We selected each hospital based on the following considerations: its capacity for performing both PCI and CABG; its position as a top-3 highest volume hospital for CABG and PCI in the located province or direct-controlled municipality; the study team\'s prior experience with participating in a clinical study; overall representation of geographic locations across the country; and the feasibility of conducting the study at the given site. All hospitals contacted agreed to participate.

![Geographic distribution of China PEACE-3VD participating Centres. PEACE-3VD, Patient-centered Evaluative Assessment of Cardiac Events three-vessel disease study.](bmjopen2015009743f02){#BMJOPEN2015009743F2}

In order to optimise the design, we conducted a pilot study at Fuwai Hospital, one of the leading cardiovascular hospitals in China. From July 2011 to September 2012, we enrolled over 1500 patients in the pilot study.

Data elements {#s2d}
-------------

We examined both the English and Chinese language literature for relevant studies to create a candidate list of potential data elements ([table 1](#BMJOPEN2015009743TB1){ref-type="table"}). Whenever possible, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) "Clinical Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease" were used to define clinical characteristics of patients' presentation, comorbidities and clinical risk factors.[@R44] Procedural characteristics were obtained using definitions from the AHA/ACCF Clinical Data Elements and Definitions and the Society of Thoracic Surgeons Adult Cardiac Surgery Database.[@R44] [@R45] Additionally, we included elements specific to the Chinese context of this study, such as the use of traditional Chinese medicine. As per prior studies, measures were selected from the existing literature whenever possible so that valid and reproducible estimates of each concept could be acquired.[@R46] [@R47]

###### 

China PEACE-3VD data elements

  Variables                          Medical record   SYNTAX Score   Baseline   Follow-up interviews       
  ---------------------------------- ---------------- -------------- ---------- ---------------------- --- ---
  Clinical characteristics                                                                                 
   Medical history                   √                                                                     
   CAD family history                                                √                                     √
   Lab testing                       √                                                                     
   Physical testing                  √                                                                     
   Image examination                 √                                                                     
   SYNTAX Score                                       √                                                    
  Treatment                                                                                                
   Progress note                     √                                                                     
   Drug treatment                    √                                                                     
   Procedures                        √                                                                     
   Secondary prevention              √                                                                     
   Secondary prevention compliance                                              √                      √   √
  Patient characteristics                                                                                  
   Basic information                                                 √                                     
   Contact                                                           √          √                      √   √
   BMI/weight/waistline                                              √          √                      √   √
   Socioeconomic status                                              √                                     √
  Outcomes                                                                                                 
   Death                                                                        √                      √   √
   MACCE                                                                        √                      √   √
   Rehospitalisation                                                            √                      √   √
   Depression                                                        √          √                      √   √
   EQ-5D                                                             √          √                      √   √
   SAQ                                                               √          √                      √   √
   Blood pressure                    √                                          √                      √   √
   Blood glucose                     √                                                                 √   √
   Blood lipid                       √                                                                 √   √
   Hepatic function                  √                                                                 √   √
   Renal function                    √                                                                 √   √

BMI, body mass index; CAD, coronary artery disease; EQ-5D, EuroQol Questionnaire; MACCE, major adverse cardiac and cerebrovascular event; SAQ, Seattle Angina Questionnaire.

China PEACE-3VD seeks to evaluate a broad range of outcomes. The primary outcome measure is the composite measure of MACCE (major adverse cardiac and cerebrovascular events, the composite end point of all-cause mortality, non-fatal myocardial infarction, stroke and additional coronary revascularisation) at 1 year. The major secondary end points are PROMs at 1 year. The study used the EQ-5D instrument as a measure of generic health-related quality of life,[@R48] [@R49] which also enables the estimation of utilities, and the Seattle Angina Questionnaire (SAQ), to assess condition-specific functioning and quality of life.[@R50] [@R51] Psychosocial status was assessed for depressive symptoms (8-item Patient Health Questionnaire: PHQ-8).[@R52] The detailed questionnaires are available in the online supplementary materials.

Medical record abstraction {#s2e}
--------------------------

Coordinators from each local site scanned all medical charts of patients in either the prospective or registry cohorts, then transmitted the scanned copy to the coordinating centre through the mail on encrypted, password-protected flash drives to the coordinating centre. The medical records were evaluated for completeness and de-identified through covering all personal information in the medical charts. The medical charts included the patients' cardiac and non-cardiac history, non-invasive testing (both, the reports and the recorded ECGs), laboratory results, in-hospital medications and procedures, in-hospital complications, discharge medications and discharge disposition. This information was abstracted by a group of trained abstractors under the supervision of trained quality control personnel, cardiologists and cardiac surgeons. The China PEACE-3VD Study adhered to rigorous standards for medical record transmission and data abstraction, similar to the previously published China PEACE-Retrospective Acute Myocardial Infarction Study and the Percutaneous Coronary Intervention Study.[@R32] [@R33] The case report form and quality control of medical record data abstraction are documented in the online supplementary materials.

SYNTAX Score calculation {#s2f}
------------------------

The participating hospitals sent all index catheterisation angiography discs of patients in either the prospective cohort or registry cohort to the coordinating centre through a safe transport system. Two specialty-trained cardiologists independently reviewed each angiogram. The Core Lab is calculating SYNTAX Scores. If the difference between the 2 reviewed SYNTAX Scores was larger than 5, a third physician also reviewed the angiogram and resolved disputes. Additionally, the Core Lab is calculating scores on each lesion.

Participant interviews {#s2g}
----------------------

We interviewed participants in the prospective cohort during their index hospitalisation and at 1-month, 6-month and 12-month intervals. Follow-up interviews were conducted face to face whenever possible. However, if a patient was unable or unwilling to return to the coordinating hospital, then a telephone interview was acceptable.

Central project managers provided 1-h standardised training to all interviewers, which included training on interview skills, and described the significance of each question during the initial meeting. To ensure coordinators' understanding of inclusion and exclusion criteria and study processes, two project managers conducted on-site monitoring within 2 months of the initial meeting at all sites. The second on-site monitoring visit was conducted 6 months after the initiation of the study, to observe follow-up interviews. All interviews were automatically recorded and transmitted to the coordinating centre. We then randomly selected 10% of these records for review by project managers to ensure adherence to study protocol.

Data management {#s2h}
---------------

We treated all data as protected health information and stored it securely in an encrypted and password-protected database at the coordinating centre. We securely stored paper charts in a locked room.

We developed data management procedures using tablet and web-based technology to ensure accurate, efficient and real-time data collection and analysis. The collection, shipping and receipt of data carriers were tracked by the coordinating centre.

Statistical analysis {#s2i}
--------------------

We will report summary statistics for patient demographic, clinical, psychosocial and behavioural characteristics; use of diagnostic tests; treatments received; and the guideline adherence and appropriateness of in-hospital treatment strategies. We will calculate summary statistics for MACCE, as well as PROMs within 1, 6 and 12 months after enrolment. In order to identify risk factors associated with treatment appropriateness and outcomes, we will use parametric and non-parametric tests for bivariate analyses, such as t test, χ^2^ test, Fisher\'s exact test and Wilcoxon rank sum tests. Moreover, multivariable regression analyses, including linear, logistic, Cox proportional hazard and Poisson models, will be used to assess the factors' association with outcomes after adjusting for potential confounders. As patients are clustered within centres and different measurement points of outcomes are clustered within patients, the analyses will account for clustering in the data (eg, generalised estimating equations or random effects models). Some missing data are expected. We will evaluate any potential selection biases introduced by missing data and conduct inverse probability weighting when appropriate, based on a propensity model, for participation in the follow-up assessments, to preferentially weight the data of patients who were most like the patients with missing data regarding outcome measures. In addition, propensity score matching and instrumental variable methods will be implemented to minimise confounding and selection bias, if necessary.

Sample size calculation {#s2j}
-----------------------

The current study is primarily a descriptive one to generate information on how patients with CCAD are treated and what outcomes they experience. The 1-year enrolment period and estimated entire sample size of eligible patients (both enrolled and not enrolled) of 4000 was determined based on both feasibility and consideration of adequate statistical precision for describing the treatment decisions, guidelines adherence and appropriateness of treatment (see online supplementary materials). We anticipated that the rate of MACCE for the entire cohort was 8% and hypothesised that at least 50% of eligible patients enrolled into the prospective cohort, and the loss-to-follow up rate was less than 10%. The projected sample size was calculated to achieve 84% statistical power at a two-sided 0.05 significance level to detect a primary end point difference of 4%.

We will report on the results of this study by presenting research abstracts at international conferences and by publishing original articles in peer-reviewed journals. Important findings will be shared with participating hospitals and policymakers to promote quality monitoring, quality improvement and the efficient allocation and use of coronary revascularisation procedures in China as well as the rest of the world.

Progress to date {#s2k}
----------------

Twenty-four hospitals agreed to participate in the study. All participating sites are tertiary teaching hospitals capable of performing both CABG and PCI. Six sites are located in Northwest China, five in North China, seven in East China and six in South Central China. The distribution of sites by province and region is shown in [figure 2](#BMJOPEN2015009743F2){ref-type="fig"}.

As of December 2013, we had consecutively enrolled 2339 patients into the prospective cohort, with an additional 2297 patients enrolled into the registry cohort. We began medical record data abstraction and SYNTAX Score calculations in January 2015, and have abstracted 3472 (75.2%) medical records and calculated SYNTAX Scores of 3297 (71.4%) patients. We have also compared demographic and clinical characteristics between the prospective and registry cohorts ([table 2](#BMJOPEN2015009743TB2){ref-type="table"}). Patients in the prospective cohort were more likely to be younger and male compared to those in the registry cohort.

###### 

Baseline characteristics and cumulative outcomes of patients enrolled and not enrolled in China PEACE-3VD\*

  Characteristics                 Enrolled (n=2089)   Not enrolled (n=1383)   p Value
  ------------------------------- ------------------- ----------------------- ---------
  Age, years                      62.4±9.8            63.4±10.3               0.007
  Male, %                         70.7                67.5                    0.051
  No insurance, %                 25.5                22.7                    0.059
  Diabetes mellitus, %            27.8                25.7                    0.163
  Hypertension, %                 67.0                65.3                    0.306
  Prior MI, %                     33.5                34.9                    0.414
  Prior heart failure, %          2.7                 3.3                     0.370
  Prior stroke, %                 11.4                12.8                    0.228
  LVEF \<40%, %                   5.6                 4.6                     0.207
  SYNTAX Scores                   22.0±11.0           22.1±11.3               0.791
  One year outcomes, %                                                        
   MACCE                          8.3                                         
   All-cause death                2.9                                         
   MI                             1.4                                         
   Stroke                         0.9                                         
   Additional revascularisation   4.3                                         

\*This table included all available data as of July 2015, and the database was not locked.

CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infraction.

The follow-up interviews have been completed. We have interviewed 96% of all enrolled patients at 1 month, 93% at 6 months and 94% at 12 months. We found that the 1-year MACCE and all-cause mortality rates of prospective cohort patients with available outcomes data are 8.3% and 2.9%, respectively ([table 2](#BMJOPEN2015009743TB2){ref-type="table"}).

Discussion {#s3}
==========

The China PEACE initiative provides a platform for translating knowledge into improved care in various settings of cardiovascular diseases in China. As one of five initial studies from the China PEACE initiative, China PEACE-3VD is a multicentre prospective study designed to develop a repository of data that describes the current presentation, treatment and 1-year outcomes for CCAD in China. This project aims to provide answers to questions about contemporary practice patterns, including variation among institutions and physicians, in procedure use and adjunctive therapy, as well as the appropriateness of treatment and adherence to current guidelines of revascularisation procedures for CCAD. The findings of the China PEACE-3VD Study will be shared with participating sites for further quality improvement initiatives, and with the Chinese government to help inform policy improvement and change.

Inappropriate use of revascularisation procedures is a major problem in developed countries.[@R18] Chan and colleagues used Appropriate Use Criteria to identify that nearly all acute PCIs in the National Cardiovascular Data Registry CathPCI Registry were appropriate, while PCI treatment during 49.6% of non-acute cardiac catheterisations were classified as inappropriate or uncertain.[@R20] Another study reached similar conclusions using data from the Clinical Outcomes Assessment Programme in Washington State.[@R21] With use of New York State\'s Cardiac Surgery Reporting System and the Percutaneous Coronary Interventions Reporting System, Hannan and colleagues found that 1% of CABG and 14% of PCI were incongruous with current guidelines.[@R18]

The use of CABG as well as of PCI is expanding rapidly in China. The very high ratio of PCI/CABG (13:1) has recently evoked a national debate prompting close examination of the appropriateness of revascularisation. This disproportionate ratio may be somewhat explained by the limited number of cardiac surgeons in China. However, long-term outcomes favour CABG for patients with CCAD, especially those with high SYNTAX Scores.[@R8] With inadequate quality measurement and incentives on appropriateness of procedures,[@R26] and a pervasive culture of retribution from family members of patients who die or have adverse events during hospitalisation,[@R53] [@R54] clinicians may concentrate on in-hospital and short-term outcomes rather than long-term outcomes and quality of life, leading them to ignore the appropriateness guidelines and offer less-invasive procedures. In the setting of stable CCAD, for which inappropriate procedures have been frequently described in other settings, the chosen treatment may not be suitable for individual patients. Using widely accepted guidelines and Appropriate Use Criteria, the China PEACE-3VD Study will provide a unique opportunity to thoroughly assess the appropriateness and adherence to current guidelines of revascularisation choices, as well as the association of treatment appropriateness with long-term events and PROMs.[@R7] [@R15] [@R17] [@R34] [@R37] Further analysis of risk factors for inappropriate revascularisation will provide evidence for the 'inappropriate revascularisation debate' in China, and guide future quality improvement initiatives.

We also expect that the knowledge generated from the China PEACE-3VD Study will be useful internationally. Many developing countries are undergoing a similar epidemiological transition,[@R55] with great strides in increasing accessibility of care, but limited monitoring of the appropriateness and quality of care. Through carefully evaluating the appropriateness of treatment, and roles of clinicians and patients in the decision-making process, we may provide valuable evidence for other countries experiencing comparable challenges. Though large trials have illuminated specific outcomes after CABG and PCI, the recovery trajectories of patients who undergo these interventions in real-world practice may be different from those in trial settings. Further analysis of the relationship between revascularisation selection and patients' quality of life and functional status may provide evidence for more wealthy countries to guide cardiac rehabilitation programmes.

The China PEACE-3VD Study is distinctive from many prospective observational studies by its use of data quality control strategies that are commonly adopted by large clinical trials. The study has devoted significant attention to data quality at multiple stages, including coordinators' training and certification, data abstraction and interview monitoring. Our quality control and assurance strategies help ensure the data quality, and promote the translation of knowledge from China PEACE-3VD Study into action.

Our study has several limitations. Only the patients who agreed and signed the informed consent forms were prospectively enrolled and followed. This may have caused selection bias. However, we were able to collect basic information on the index hospitalisation of patients not enrolled, making it possible to assess the influence of enrolment and patients' preference on the representativeness of the study. Additionally, our participating sites are all large teaching hospitals, which may only represent large urban centres in China and may not be reflective of the care patients receive in smaller or rural hospitals. However, our work can still inform quality improvement projects that may reach these smaller hospitals, having the potential to improve care throughout China. For the baseline interview, we only collected data regarding patients' symptoms, treatment and quality of life before hospitalisation. However, interview details may have been influenced for patients undergoing ad hoc PCI that occurred prior to the baseline interview.

As one of five initial studies from the China PEACE initiative, China PEACE-3VD is a multicentre prospective study, seeking to describe the current presentation, treatment and patient outcomes of non-acute CCAD in a multicentre sample of large hospitals in China. This project will provide answers to questions about contemporary practice patterns, including variation among institutions in procedure use and adjunctive therapy, as well as the appropriateness and guideline adherence of revascularisation procedures for CCAD. The findings of the China PEACE-3VD Study will be shared with participating sites, for further quality improvement initiatives, and with the government, to help research findings inform policy.
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